These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 28260416)
1. Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts. Sormani MP Mult Scler; 2017 Mar; 23(3):378-381. PubMed ID: 28260416 [TBL] [Abstract][Full Text] [Related]
2. The use of MRI as an outcome measure in clinical trials. Li DK; Li MJ; Traboulsee A; Zhao G; Riddehough A; Paty D Adv Neurol; 2006; 98():203-26. PubMed ID: 16400836 [TBL] [Abstract][Full Text] [Related]
4. Biomarkers of treatment response in multiple sclerosis. Buck D; Hemmer B Expert Rev Neurother; 2014 Feb; 14(2):165-72. PubMed ID: 24386967 [TBL] [Abstract][Full Text] [Related]
5. Development of biomarkers in multiple sclerosis. Bielekova B; Martin R Brain; 2004 Jul; 127(Pt 7):1463-78. PubMed ID: 15180926 [TBL] [Abstract][Full Text] [Related]
6. 'No evidence of disease activity' - is it an appropriate surrogate in multiple sclerosis? Hegen H; Bsteh G; Berger T Eur J Neurol; 2018 Sep; 25(9):1107-e101. PubMed ID: 29687559 [TBL] [Abstract][Full Text] [Related]
7. Neurofilaments as biomarkers in multiple sclerosis. Teunissen CE; Khalil M Mult Scler; 2012 May; 18(5):552-6. PubMed ID: 22492131 [TBL] [Abstract][Full Text] [Related]
8. Developing Biomarkers for MS. Gnanapavan S; Giovannoni G Curr Top Behav Neurosci; 2015; 26():179-94. PubMed ID: 25502545 [TBL] [Abstract][Full Text] [Related]
9. Multiple sclerosis: use of MRI in evaluating new therapies. Miller DH Semin Neurol; 1998; 18(3):317-25. PubMed ID: 9817536 [TBL] [Abstract][Full Text] [Related]